Tasly Pharmaceutical Group Co., Ltd.

Overview

Tasly Pharmaceutical Group Co., Ltd. is a leading pharmaceutical company in China, specializing in the research, development, production, and distribution of both traditional Chinese and modern medicines. The company is known for integrating traditional Chinese medicine with modern biotechnology and pharmaceutical practices.

Therapeutic areas

API / Drug Master Files

Tasly Pharmaceutical Group Co., Ltd. holds 11 active (12 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• GLIPIZIDEActive2024-12-22
• OBETICHOLIC ACIDActive2023-05-04
• DABIGATRAN ETEXILATE MESYLATEActive2020-12-02
• TOFACITINIB CITRATEActive2019-09-27
• SORAFENIB TOSYLATEActive2015-06-30
• CEFSULODINActive2015-04-02
• IRON SUCROSEActive2014-10-08
• DIMETHYL FUMARATEActive2014-09-28
• GEFITINIBActive2014-09-03
• PROMESTRIENEActive2014-06-06
• TIGECYCLINEActive2013-08-19
• DIPYRIDAMOLE USPInactive2014-08-14

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to Tasly Pharmaceutical Group Co., Ltd. in our records. PharmaTek screens the full directory against live FDA enforcement data.